These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17224711)

  • 21. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.
    Citrome LL; Holt RI; Zachry WM; Clewell JD; Orth PA; Karagianis JL; Hoffmann VP
    Ann Pharmacother; 2007 Oct; 41(10):1593-603. PubMed ID: 17785613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effectiveness of guideline implementation strategies on improving antipsychotic medication management for schizophrenia.
    Owen RR; Hudson T; Thrush C; Thapa P; Armitage T; Landes RD
    Med Care; 2008 Jul; 46(7):686-91. PubMed ID: 18580387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evaluation of monitoring practices in patients on second generation antipsychotics.
    Nguyen D; Brakoulias V; Boyce P
    Australas Psychiatry; 2009 Aug; 17(4):295-9. PubMed ID: 19585292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic side effects of second generation antipsychotic agents in antipsychotic-naïve patients: one-month prospective evaluation.
    Tarricone I; Serretti A; Gozzi BF; Mandelli L; Grieco D; Mellini L; Biagini S; Berti B; Berardi D
    Psychiatry Res; 2008 Jan; 157(1-3):269-71. PubMed ID: 17961714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness.
    Megna JL; Kunwar AR; Mahlotra K; Sauro MD; Devitt PJ; Rashid A
    J Psychiatr Pract; 2007 Mar; 13(2):129-37. PubMed ID: 17414692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polypharmacy with second-generation antipsychotics: a review of evidence.
    Pandurangi AK; Dalkilic A
    J Psychiatr Pract; 2008 Nov; 14(6):345-67. PubMed ID: 19057237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Schizophrenia, obesity, and antipsychotic medications: what can we do?
    Citrome L; Vreeland B
    Postgrad Med; 2008 Jul; 120(2):18-33. PubMed ID: 18654065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
    Wheeler AJ
    Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic syndrome and mental illness.
    Newcomer JW
    Am J Manag Care; 2007 Nov; 13(7 Suppl):S170-7. PubMed ID: 18041878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atypical antipsychotic drugs, diabetes and ethnicity.
    Ananth J; Kolli S; Gunatilake S; Brown S
    Expert Opin Drug Saf; 2005 Nov; 4(6):1111-24. PubMed ID: 16255668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophrenia.
    Taylor D; Hayhurst K; Kerwin R
    Int Clin Psychopharmacol; 2007 May; 22(3):133-6. PubMed ID: 17414738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abnormal glucose metabolism in patients treated with antipsychotics.
    Scheen AJ; De Hert MA
    Diabetes Metab; 2007 Jun; 33(3):169-75. PubMed ID: 17412628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
    Newcomer JW
    J Clin Psychiatry; 2007; 68 Suppl 1():20-7. PubMed ID: 17286524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Schizophrenia, obesity and pharmacotherapy-associated weight gain].
    Carpiniello B; Corda E; Maccioni R; Pinna F
    Clin Ter; 2008; 159(5):299-306. PubMed ID: 18998030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behavioral therapy for weight loss in patients with schizophrenia.
    Ganguli R
    J Clin Psychiatry; 2007; 68 Suppl 4():19-25. PubMed ID: 17539696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antipsychotic treatment and the prevalence of diabetes among elderly patients in psychiatric rehabilitation.
    Klebovich A; Hankó B; Orbán K; Zelkó R
    Arch Gerontol Geriatr; 2009; 48(1):19-21. PubMed ID: 17950480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weighing in: emergent diabetes mellitus and second-generation antipsychotics.
    Dufresne RL
    Ann Pharmacother; 2007 Oct; 41(10):1725-7. PubMed ID: 17785611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychofarmacology in the prevention of somatic comorbid diseases in mentally ill patients.
    Jukić V; Petrović Z; Brecić P; Krizaj A; Savić A; Baceković A; Bilić P; Susac J; Mandić A; Prazen I
    Psychiatr Danub; 2009 Sep; 21(3):350-5. PubMed ID: 19794355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gender differences in the prevalence of diabetes mellitus in chronic hospitalized patients with schizophrenia on long-term antipsychotics.
    Chen DC; Zhou MA; Zhou DH; Xiu MH; Wu GY; Kosten TR; Zhang XY
    Psychiatry Res; 2011 Apr; 186(2-3):451-3. PubMed ID: 20797801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.